Post-Trial Supply
How Can Treatment Continue After a Clinical Trial Ends?
Post-Trial Supply programs provide a cost-effective solution for trial sponsors to support patients who benefitted from treatment with an investigational medicine during a clinical trial to continue treatment after trial completion.
Tanner Pharma is a full-service provider which designs and delivers compliant post-trial supply solutions on a global basis.
Our process enables ethical trial close-out while maintaining patient access to treatment through a controlled distribution channel. We support sponsors with program design and execution through the management of regulatory submissions, navigation of complex country-specific regulatory requirements, and the provision of end-to-end GxP-compliant logistics, secondary labeling, and packaging services.
Scenarios for Post-Trial Supply
Early closure of a trial (e.g. futility) which still has responding patients.
Access for patients rolling off a trial per protocol in a country where the product is not available or may never be available.
Extending treatment from the main trial in a format less expensive than a full Long-Term Extension Trial.
Complying with regulations in countries which require Post-Trial Access.
Not Sure Where to Start?
Explore our Medicine Access 101 guide for patients and HCPs.
Core Services
Program Management
Regulatory Compliance
Regulatory Compliance
Supply Chain & Logistics
Program Management
Quality Assurance
Pharmacovigilance
Pharmacovigilance
Supply Chain & Logistics
Quality Assurance
How We Deliver Access Solutions
Explore real-world examples of how we navigate regulatory, geographic and supply complexities to deliver compliant, global access to essential therapies.